Holen Sie sich die Stockscreener-App
1.175
14.59%
-0.195
Schlusskurs vom Vortag:
$1.37
Offen:
$1.39
24-Stunden-Volumen:
3.72M
Relative Volume:
1.15
Marktkapitalisierung:
$152.79M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-93.61M
KGV:
-0.5569
EPS:
-2.11
Netto-Cashflow:
$-71.16M
1W Leistung:
-4.87%
1M Leistung:
+28.23%
6M Leistung:
+47.31%
1J Leistung:
+4.47%
1-Tages-Spanne:
$1.16
$1.40
1-Wochen-Bereich:
$1.16
$1.51
52-Wochen-Spanne:
$0.5062
$1.51
Immunic Inc Stock (IMUX) Company Profile
Firmenname
Immunic Inc
Sektor
Branche
Telefon
(332) 255-9818
Adresse
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
1.1711 | 178.74M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.28 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.73 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
695.77 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.53 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.50 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Eingeleitet | Roth Capital | Buy |
| 2025-09-29 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-25 | Eingeleitet | William Blair | Outperform |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-27 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-04-15 | Eingeleitet | Aegis Capital | Buy |
| 2021-03-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-07 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-06-05 | Eingeleitet | Wedbush | Outperform |
| 2020-05-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-11 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Immunic Inc Aktie (IMUX) Neueste Nachrichten
New European patent covers all dosing regimens of experimental MS therapy - Multiple Sclerosis News Today
A Look At Immunic (IMUX) Valuation As Reverse Split Proposal And Conference Appearance Draw Attention - simplywall.st
Volume Recap: What makes Immunic Inc stock attractive today2026 Closing Moves & Consistent Return Investment Signals - baoquankhu1.vn
Immunic at Leerink Global Healthcare Conference: Strategic Insights on MS Drug By Investing.com - Investing.com India
Immunic at Leerink Global Healthcare Conference: Strategic Insights on MS Drug - Investing.com Nigeria
Immunic secures European patent for vidofludimus calcium dosing By Investing.com - Investing.com Canada
Small cap wrap: Immunic, AtaiBeckley, Standard Uranium, Trust Stamp… - Proactive Investors
Immunic secures European patent for vidofludimus calcium dosing - Investing.com Nigeria
Immunic (IMUX) Secures Key European Patent for Vidofludimus Calc - GuruFocus
Biopharmaceutical company Immunic, Inc. announced that it has been granted a key European patent, which will provide important protection for the administration regimen related to Vidofludimus calcium. - Bitget
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium - PR Newswire
Immunic secures European patent for MS drug candidate vidofludimus calcium - Proactive financial news
What makes Immunic Inc. (10VA) stock appealing to growth investorsOil Prices & Real-Time Volume Surge Alerts - Naître et grandir
Earnings Update: Whats the analyst consensus on Immunic IncDay Trade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
HC Wainwright Has Bearish Estimate for Immunic Q1 Earnings - MarketBeat
Immunic, Inc. Announces Participation in Investor Conferences Scheduled for March 2026 - geneonline.com
Dentons Advises Immunic, Inc. on Private Placement and Royalty Transactions - Dentons
IMUX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Immunic to Participate in Investor Conferences in March - The Malaysian Reserve
Immunic to present at healthcare investor conferences in March - Yahoo Finance
Immunic execs line up March investor Q&As and webcasts - Stock Titan
Head to Head Review: Neuphoria Therapeutics and Immunic - National Today
Reverse stock split vote at Immunic (NASDAQ: IMUX) tied to Nasdaq listing - Stock Titan
Multiple Sclerosis Competitive Landscape 2026: 75+ Companies, 80+ Pipeline Therapies, 15+ Key FDA & Clinical Milestones Driving the Future of Multiple Sclerosis Treatment, analyses DelveInsight - Barchart.com
Immunic, Inc.Common Stock (NQ: IMUX - The Chronicle-Journal
H.C. Wainwright cuts Immunic stock price target on share count changes - Investing.com Australia
HC Wainwright Issues Pessimistic Forecast for Immunic (NASDAQ:IMUX) Stock Price - MarketBeat
Aug Opening: Can Immunic Inc sustain earnings growthMarket Volume Summary & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Immunic secures $400M to support late-stage MS trialsICYMI - Yahoo Finance
Immunic (NASDAQ:IMUX) Posts Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
COMMODORE CAPITAL LP Acquires Significant Stake in Immunic Inc - GuruFocus
BVF group details large Immunic (IMUX) pre-funded and common warrants - Stock Titan
IMMUNIC (IMUX) director Robert Nagel files initial insider Form 3 - Stock Titan
Immunic CEO on $400m financing, phase 3 MS plans - Proactive financial news
Immunic sets stage for phase 3 MS data readout after $400M financing - Proactive financial news
Immunic: Fourth Quarter Financial Overview - Bitget
IMMUNIC, INC. SEC 10-K Report - TradingView
Immunic: Q4 Earnings Snapshot - Barchart.com
Immunic (NASDAQ: IMUX) details 2025 loss and $200M private placement - Stock Titan
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update - PR Newswire
Immunic, Inc. (NASDAQ:IMUX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: ProQR (PRQR), Immunic (IMUX) and Harmony Biosciences Holdings (HRMY) - The Globe and Mail
Commodore holds 13.35M IMUX shares, mostly warrant-based (IMUX) - Stock Titan
Trails Edge reports 11.45M-share position in Immunic (IMUX) via warrants - Stock Titan
Why did IMUX stock surge 33% pre-market today? - MSN
IMUX Stock Price, Forecast & Analysis | IMMUNIC INC (NASDAQ:IMUX) - ChartMill
What’s the beta of Immunic Inc. stock2025 Earnings Impact & Long-Term Investment Growth Plans - mfd.ru
Why Immunic Inc. stock is seen as undervaluedJuly 2025 Macro Moves & Safe Entry Trade Reports - mfd.ru
Vivo Opportunity files for Immunic (IMUX): 9.99% stakes via exercisable warrants - Stock Titan
What Does the Market Think About Immunic Inc? - Benzinga
Immunic Therapeutics - The Pharma Letter
Finanzdaten der Immunic Inc-Aktie (IMUX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunic Inc-Aktie (IMUX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tardio Jason | President and COO |
Jun 05 '25 |
Buy |
0.79 |
12,512 |
9,884 |
12,512 |
| Vitt Daniel | CEO and Director |
Jun 04 '25 |
Buy |
0.77 |
15,000 |
11,550 |
29,000 |
| Neermann Joerg | Director |
Jun 04 '25 |
Buy |
0.77 |
70,000 |
53,900 |
170,000 |
| Neermann Joerg | Director |
Jun 05 '25 |
Buy |
0.76 |
30,000 |
22,800 |
200,000 |
| Whaley Glenn | Chief Financial Officer |
Jun 03 '25 |
Buy |
0.71 |
45,000 |
32,076 |
95,510 |
| Rudick Richard Alan | Director |
Jun 03 '25 |
Buy |
0.70 |
143,075 |
100,024 |
230,375 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):